Voluntary nationwide recall: Duloxetine (Towa – October)

Dec. 2024Pharmacy Updates

Towa Pharmaceutical is recalling one lot, lot 220128, of Duloxetine Delayed-Release Capsules, USP, 20 mg. Duloxetine is used to treat anxiety, depression, and certain types of nerve pain.

This drug is being recalled because it contained an impurity called N-nitroso-duloxetine. According to the FDA, nitrosamine impurities may increase the risk of cancer if people are exposed to them above acceptable levels and over long periods of time. Additionally, the FDA added that someone who is taking a drug that contains nitrosamines at or below the acceptable daily intake limits every day for several years is not expected to have an increased risk of cancer.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA report and website below. If you have an affected lot of Duloxetine, The FDA advises that you should stop using the product and return it to the place of purchase or throw it away.

As of Oct. 23, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.


Recent Announcements

UPMC-GoHealth Urgent Care centers opening

UPMC has formed a joint venture with GoHealth Urgent Care. MedExpress locations in PA and WV and UPMC Urgent Care and Express Care centers are transitioning to UPMC-GoHealth Urgent Care centers.
Jun. 2025Important Notices

Fostering Trust in Vaccinations Through Shared Decision Making

Please join us for a live, CME-accredited webinar on Thursday, September 11, from noon to 1 p.m. that will provide an overview of fostering trust in vaccinations through shared decision making.
May 2025Education/Webinars

Pause in Prior Authorization Policies

On April 1, 2025, we announced that UPMC Health Plan would start requiring prior authorization for certain services. Please note that we are delaying or changing the implementation of prior authorization for some of these services, as described below.
May 2025Important Notices